Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 3Phase 2/3 2Phase 1/2 2Phase 4 1

Status

Completed 221Terminated 69Unknown 30Active not recruiting 28Recruiting 27Withdrawn 17Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Mantle-Cell 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Bortezomib × Clear all
NCT07614360 2026-05-29

DREAMM-16

GlaxoSmithKline

Phase 2 Not yet recruiting
120 enrolled
Plasma cell

Multiple Myeloma

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07247097 2025-11-25

ELDORADO

Massachusetts General Hospital

Phase 2 Not yet recruiting
160 enrolled
Plasma cell

Multiple Myeloma

NCT06656221 2024-11-19

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

Ruijin Hospital

Phase 2 Not yet recruiting
29 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡